OBJECTIVE: Antiretroviral therapy (ART) has been implicated in bone loss in HIV. The role of inflammation and vitamin D is unclear and better investigated in ART-naive individuals. DESIGN AND METHODS: This is a 48-week, prospective cohort study to compare baseline and change in hip and spine bone mineral density (BMD) measured by dual-energy X-ray absorptiometry in HIV-infected, ART-naive adults and healthy controls matched by age, sex, and race. We also studied associations between bone loss and inflammation markers and plasma 25-hydroxyvitamin D [25(OH)D] using logistic regression. RESULTS: Forty-seven HIV-infected adults and 41 controls were included. Baseline 25(OH)D, BMD at total hip, trochanter, and spine, and prevalence of osteopenia and osteoporosis were similar between groups. In the HIV-infected group, total hip and trochanter, but not spine, BMD decreased over 48 weeks [hip -0.005 (-0.026-0.008) g/cm², P = 0.02 within group; trochanter -0.013 (-0.03-0.003), P < 0.01]. BMD did not change at any site within controls. The HIV-infected group was more likely to have bone loss at the trochanter (P = 0.03). This risk persisted after adjustment for age, sex, race, BMI, smoking, and hepatitis C (odds ratio 4, 95% confidence interval 1.2-15.8). In the HIV-infected group, higher interleukin-6 concentrations (P = 0.04) and Caucasian race (P < 0.01) were independently associated with progression to osteopenia or osteoporosis, but not 25(OH)D levels. CONCLUSION: BMD at the total hip and trochanter sites decreased in the HIV-infected, ART-naive adults, but not controls, over this 48-week study. Higher serum interleukin-6 concentrations were associated with progression to osteopenia or osteoporosis status in the HIV-infected group.
OBJECTIVE: Antiretroviral therapy (ART) has been implicated in bone loss in HIV. The role of inflammation and vitamin D is unclear and better investigated in ART-naive individuals. DESIGN AND METHODS: This is a 48-week, prospective cohort study to compare baseline and change in hip and spine bone mineral density (BMD) measured by dual-energy X-ray absorptiometry in HIV-infected, ART-naive adults and healthy controls matched by age, sex, and race. We also studied associations between bone loss and inflammation markers and plasma 25-hydroxyvitamin D [25(OH)D] using logistic regression. RESULTS: Forty-seven HIV-infected adults and 41 controls were included. Baseline 25(OH)D, BMD at total hip, trochanter, and spine, and prevalence of osteopenia and osteoporosis were similar between groups. In the HIV-infected group, total hip and trochanter, but not spine, BMD decreased over 48 weeks [hip -0.005 (-0.026-0.008) g/cm², P = 0.02 within group; trochanter -0.013 (-0.03-0.003), P < 0.01]. BMD did not change at any site within controls. The HIV-infected group was more likely to have bone loss at the trochanter (P = 0.03). This risk persisted after adjustment for age, sex, race, BMI, smoking, and hepatitis C (odds ratio 4, 95% confidence interval 1.2-15.8). In the HIV-infected group, higher interleukin-6 concentrations (P = 0.04) and Caucasian race (P < 0.01) were independently associated with progression to osteopenia or osteoporosis, but not 25(OH)D levels. CONCLUSION: BMD at the total hip and trochanter sites decreased in the HIV-infected, ART-naive adults, but not controls, over this 48-week study. Higher serum interleukin-6 concentrations were associated with progression to osteopenia or osteoporosis status in the HIV-infected group.
Authors: Y Ishimi; C Miyaura; C H Jin; T Akatsu; E Abe; Y Nakamura; A Yamaguchi; S Yoshiki; T Matsuda; T Hirano Journal: J Immunol Date: 1990-11-15 Impact factor: 5.422
Authors: M E Ooms; P Lips; J C Roos; W J van der Vijgh; C Popp-Snijders; P D Bezemer; L M Bouter Journal: J Bone Miner Res Date: 1995-08 Impact factor: 6.741
Authors: Jane A Cauley; Michelle E Danielson; Robert M Boudreau; Kimberly Yz Forrest; Joseph M Zmuda; Marco Pahor; Frances A Tylavsky; Steven R Cummings; Tamara B Harris; Anne B Newman Journal: J Bone Miner Res Date: 2007-07 Impact factor: 6.741
Authors: Joseph D Perazzo; Allison R Webel; S M Khurshid Alam; Abdus Sattar; Grace A McComsey Journal: J Assoc Nurses AIDS Care Date: 2018-03-28 Impact factor: 1.354
Authors: James Watt; Jonathan Schuon; Jacob Davis; Tekeda F Ferguson; David A Welsh; Patricia E Molina; Martin J J Ronis Journal: Alcohol Clin Exp Res Date: 2019-10-01 Impact factor: 3.455
Authors: A Carr; B Grund; J Neuhaus; A Schwartz; J I Bernardino; D White; S Badel-Faesen; A Avihingsanon; K Ensrud; J Hoy Journal: HIV Med Date: 2015-04 Impact factor: 3.180
Authors: Philip M Grant; Virginia Sheikh; Rebecca DerSimonian; Adam Rupert; Gregg Roby; Alice Pau; Michael C Sneller; Sheryl-Vi Rico; Todd T Brown; Irini Sereti Journal: AIDS Res Hum Retroviruses Date: 2015-05-21 Impact factor: 2.205